Cardiovascular polypills from Cipla, Dr Reddy's to enter trial in UK and India
This article was originally published in Scrip
Cipla hopes to start Indian trials this year with its "primary" version of the "polypill", which comprises three antihypertensives at half the standard dose and a statin, and is aimed at preventing heart attacks and strokes. Another Indian company, Dr Reddy's Laboratories, also appears to have made progress in developing its polypill, for those with cardiovascular disease, with trials ongoing globally.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.